TCR T cell therapy, instead, consists in the overexpression of specific TCR recognizing cancer type-specific antigens (e.g., cancer–testis antigen) or patient-specific neoantigens, but unlike MHC-independent CAR T, this approach requires MHC-matching with the patient [83]. Here, HLA-C is linked to cancer.